Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Feb;20(1):1-9.
doi: 10.1007/s10238-019-00592-5. Epub 2019 Nov 11.

Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis

Hailing Liu  1 , Nan Yang  1 , Shan Meng  1 , Yang Zhang  1 , Hui Zhang  1 , Wanggang Zhang  2
Affiliations
Meta-Analysis

Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis

Hailing Liu et al. Clin Exp Med. 2020 Feb.

Abstract

Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still a controversial issue. Therefore, we conducted a systematic review and meta-analysis to clarify the relationship between ICT and long-term survival in patients with MDS. A total of 14 studies involving 7242 participants were identified; the outcomes revealed that for patients with MDS, ICT resulted in a lower risk of mortality compared to those with no ICT (HR 0.57; 95% CI 0.44-0.70; P < 0.001); what is more, ICT led to a lower risk of leukemia transformation (HR 0.70; 95% CI 0.52-0.93; P = 0.016). Results of subgroup analyses based on adequate ICT or any ICT, low/int-1 IPSS or unclassified IPSS and study types indicated that the ICT had a beneficial role in all these groups of patients.

Keywords: Iron chelation therapy; Iron overload; Leukemia-free survival; Myelodysplastic syndrome; Overall survival.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65. https://doi.org/10.1182/blood-2012-03-420489 . - DOI - PubMed - PMC
    1. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013;88(10):831–7. https://doi.org/10.1002/ajh.23513 . - DOI - PubMed - PMC
    1. Waszczuk-Gajda A, Madry K, Machowicz R, Drozd-Sokolowska J, Stella-Holowiecka B, Mital A, et al. Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first polish MDS-PALG registry. Adv Clin Exp Med Off Org Wroc Med Univ. 2016;25(4):633–41. https://doi.org/10.17219/acem/62397 . - DOI
    1. Dreyfus F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev. 2008;22(Suppl 2):S29–34. https://doi.org/10.1016/S0268-960X(08)70006-7 . - DOI - PubMed
    1. Shammo JM, Komrokji RS. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Rev Hematol. 2018;11(7):577–86. https://doi.org/10.1080/17474086.2018.1486188 . - DOI - PubMed

LinkOut - more resources